Global Health Ltd (MEDANTA)
₹1,270.30
Mkt cap
₹34,156 Cr
P/E ratio
59.70
P/B
8.64
Div yield
0.04%
ROE
15.20%
ROCE
17.40%
EPS (TTM)
₹21.28
Book value
₹147
52W range
956–1,544
Sector
Healthcare
Price history
Previous close
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. [1]
NSE MEDANTABSE 543654
Health check
Mixed
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−17.73% from high₹1,270
₹956+32.88% from low₹1,544
Current
₹1,270.30
Prev close
₹1,299.70
Day
−2.26%
Price performance
1D
−2.75%
1W
+6.67%
1M
−10.68%
3M
−10.76%
6M
+10.59%
1Y
−6.61%
YTD
+4.37%
Financials
Revenue, profit & margin
P/E ratio
59.7×
MEDANTA is 35% above the sector median of 44.4×
MEDANTA59.7×
Sector median44.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 | |
| Expenses | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 | |
| Operating Profit | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 | |
| OPM % | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% | |
| Other Income | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 | |
| Interest | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 | |
| Depreciation | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 | |
| Profit before tax | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 | |
| Tax % | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% | |
| Net Profit | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 | |
| EPS in Rs | 3.80 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.90 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.72% · closed higher next day 10 of last 15
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 8 Feb '24◦ | 17 May '24◦ | 8 Aug '24◦ | 14 Nov '24◦ | 4 Feb '25◦ | 15 May '25◦ | 7 Aug '25◦ | 7 Nov '25◦ | 4 Feb '26◦ | 14 May '26◦ | 30 Jul '26◦ |
| Earnings day | +5.01% | +0.85% | −1.20% | −3.44% | +0.83% | +10.73% | −3.39% | +7.25% | −5.42% | −1.34% | +2.52% | −0.76% |
| +1 day | +5.94% | +6.96% | −6.05% | −7.85% | +1.86% | +12.23% | −5.01% | +4.55% | −6.30% | +1.77% | +2.25% | +2.01% |
| +5 days | +4.32% | +14.04% | −13.93% | −5.77% | +2.82% | +4.67% | −1.88% | +1.22% | −3.97% | +2.30% | +2.16% | +2.77% |
| +15 days | +16.72% | +3.16% | −14.68% | −3.77% | +6.46% | +14.60% | −2.19% | +4.78% | −0.47% | +3.46% | −0.12% | −0.47% |
| +30 days | +11.27% | +2.49% | −10.27% | −6.61% | +2.68% | +21.51% | −8.74% | −0.40% | −6.68% | −10.43% | +8.41% | +2.17% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202633.00%Promoter
Promoters33.00%
FIIs9.92%0.46
DIIs17.01%0.12
Public39.96%0.59
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | ₹8,448.00 | 57.74 | 1,21,469 | 0.24% | 610 | +34.17% | 7,044 | +20.56% | 17.45% |
| Manipal Health | ₹669.15 | 99.41 | 88,018 | 0.00% | 243 | −7.86% | 3,091 | +38.12% | 12.10% |
| Max Healthcare | ₹860.00 | 58.93 | 83,705 | 0.23% | 414 | −15.54% | 2,569 | +20.31% | 14.71% |
| Aster DM Quality | ₹681.15 | 164.50 | 59,374 | 0.44% | 29 | −46.12% | 1,311 | +21.60% | 11.57% |
| Fortis Health. | ₹768.15 | 54.36 | 57,992 | 0.13% | 273 | +3.39% | 2,545 | +17.46% | 13.45% |
| Narayana Hrudaya | ₹1,720.20 | 38.85 | 35,154 | 0.26% | 301 | +16.61% | 2,844 | +73.01% | 15.50% |
| Global Health | ₹1,270.30 | 59.66 | 34,156 | 0.04% | 157 | −0.18% | 1,304 | +26.50% | 17.37% |
| Median: 31 Co. | ₹509.20 | 44.38 | 6,363 | 0.00% | 30 | +17.80% | 403 | +22.28% | 14.62% |
Filings
Concall transcripts38
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Oct - Q2 FY2027 earnings conference call scheduled for November 4, 2026 at 2:00 PM IST.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 23 Oct - Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding allotment of Shares.Board Meeting Intimation for Board Meeting Intimation For Schedule Of Board Meeting For The Second Quarter & Half Year Ended September 30, 2026 Under Regulation 29 Of SEBI (LODR) 2015. 22 Oct - Board meeting on November 3, 2026 to approve Q2 and half-year FY2026-27 results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - KFin issued Regulation 74(5) certificate for quarter ended September 30, 2026; nil demat/remat activity.Intimation Under Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015 - ESG Rating Assigned By Crisil ESG Ratings & Analytics Limited. 5 Oct - Crisil assigned FY2026 ESG rating of 64 and Core ESG rating of 70 to Global Health.